GLOBUS MEDICAL INC

NYSE: GMED·Audubon, Pennsylvania·

Price
$70.50
Base IV
$53.41

Valuation snapshot

Above base case

At $70.50, the price sits between our base case ($53.41) and bull case ($72.43).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$53.41
76% of the price · range $34.52–$72.43
Price vs base case
32% above
$70.50 against $53.41
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $34.52 to bull $72.43. Values per share.

Price against each value

Bear case
$34.52
Price 104% above
No growth
…
—
Base case
$53.41
Price 32% above
Researched byClaude Opus 5.5
Valuation Nov 15, 2026 · Price as of Nov 16, 2026How we got here

What does Globus Medical do?

Globus Medical develops and sells medical devices and technologies to help surgeons treat patients with musculoskeletal disorders.

It brought in $3.1B of sales in the 12 months to Sep 2026.

Led by Keith W. Pfeil, President and Chief Executive Officer since 2025. Globus Medical, Inc. Current Report on Form 8-K (Item 5.02)

Precice intramedullary limb lengthening system and external remote controllerImage: Globus Medical, Inc.
Industry
Healthcare
Based in
Audubon, Pennsylvania
Trades on
NYSE as GMED

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 18¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 38¢ of every dollar.

  • Making what it sells31¢
  • Research and development5¢
  • Sales, marketing and admin38¢
  • Everything else it takes to operate5¢
  • Tax5¢
  • Left as profit18¢
  • Interest and other income came back in+1¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Globus Medical, and for what?

Globus Medical designs and sells medical devices and surgical tools used to treat spine, orthopedic, and chronic pain conditions. It earns revenue primarily by selling spinal implants, biologics, and orthopedic hardware used during surgeries. It also sells and leases robotic guidance, navigation, and imaging systems that assist surgeons during operations.

Hospitals, ambulatory surgery centers, and healthcare systems purchase or lease the company's devices and equipment for use by surgeons.

  • Musculoskeletal Solutions

    95%

    Implantable devices, biologics, surgical instruments, spinal cord stimulation devices, and neuromonitoring services used in spine and orthopedic procedures.

    Precice intramedullary limb lengthening system and external remote controllerImage: Globus Medical, Inc.
  • Enabling Technologies

    5%

    Advanced computer-assisted surgical systems, including robotic navigation, intraoperative imaging, and surgical planning software.

    ExcelsiusGPS surgical navigation system in an operating roomImage: Globus Medical, Inc.
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Eagleville Implant Manufacturing — Eagleville, United States. The FY2025 10-K names it as one of the main plants making Globus's spine and orthopedic implants, the bulk of company revenue, so its capacity sets how much of that output Globus makes in-house.
  • Methuen Excelsius Robotics Assembly — Methuen, United States. This is where Globus assembles its Excelsius surgical robots, which help pull through sales of its implants, so the site's output limits how fast the robot base can grow.
  • Limerick Implant Manufacturing — Limerick, United States. The 10-K names this second Pennsylvania plant as an implant manufacturing site, adding capacity and backup supply for the core musculoskeletal implant business.
  • West Carrollton Implant Manufacturing — West Carrollton, United States. The 10-K names it as an implant manufacturing site outside Pennsylvania, part of the owned plant network that supports the implant product line built up through the NuVasive merger.
  • Costa Rica Spinal Cord Stimulation Plant (Nevro) — Alajuela, Costa Rica. The 10-K says Globus makes its spinal cord stimulation products in Costa Rica; the plant came with the Nevro acquisition, so it supplies the newly added neuromodulation revenue.
See them on the globe

Globus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025

How is the business doing?

Sales grew from $789M in 2020 to $2.9B in 2025, about 30% a year.

Running the business leaves about 22¢ of each sales dollar as operating profit, up from 14¢ in 2020.

After paying for its upkeep and new investment, it had $766.6M of cash to spare in the 12 months to Sep 2026.

Sales$2.9B
20162025
Operating margin16%
20162025
Free cash flow$588.8M
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Globus Medical exists to improve the quality of life for patients suffering from musculoskeletal disorders.

“to improve the quality of life of patients with musculoskeletal disorders”

About Globus Medical

Who is responsible for the plan?

  • Keith W. PfeilPresident and Chief Executive Officer

    Keith W. Pfeil oversees the overall strategic direction, operations, and executive leadership of Globus Medical. Globus Medical designs, develops, and commercializes musculoskeletal healthcare solutions and enabling technologies to generate commercial revenue.

  • Kyle R. KlineSenior Vice President and Chief Financial Officer

    Kyle R. Kline oversees Globus Medical's global finance, accounting, and financial reporting functions as principal financial and accounting officer. Management of financial reporting, capital allocation, and budgeting directly supports commercialization and distribution of the company's musculoskeletal solutions.

Roles checked November 6, 2026.

What management says it is working on now:

Full-Year 2026 Net Sales, Full Year 2026
$3.18 billion to $3.22 billion
Globus Medical Reports Second Quarter 2026 Financial Results
Non-GAAP Diluted Earnings Per Share, Full Year 2026
$4.95 to $5.05
Globus Medical Reports Second Quarter 2026 Financial Results
Adjusted Gross Profit Margin, Over time
Mid-70s percentage
Globus Medical Reports Second Quarter 2026 Financial Results
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is slowing. In Q3 2026 it sold 1% less than a year earlier. The year before, quarters averaged 20%.

Its operating margin is wider than a year ago: 23¢ per sales dollar, against 18¢.

Since Nov 2026 the share price has fallen 11%, from $79.47 to $70.50.

Bull $72.43Base $53.41Bear $34.52Nov 3Nov 16 · $70.50
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start November 3, 2026.

Recently

Coming up

Our own estimate moved too: the base case went from $66.01 to $53.41 a share between our last two valuations. The biggest reason: Total revenue growth, quarterly YoY moved from an unreported prior value to -0.7%, as reported in GMED Q3 2026 8-K.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Surgeon Adoption and Hospital Purchasing Decisions

    The company must convince surgeons and hospitals that its products are attractive alternatives to competitors. Hesitation to adopt new techniques or lack of training could reduce sales.

    From the company's own filingsWould hit how fast sales growGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025

  2. Third-Party Reimbursement and Pricing Pressure

    Reductions or denials of insurance coverage by Medicare, Medicaid, or private payers could limit patient access to procedures and force price reductions, lowering profit margins.

    From the company's own filingsWould hit how much of each sale it keepsGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025

  3. Dependence on Specialized Third-Party Suppliers

    Globus relies on a small number of suppliers for finished goods, raw materials, and donor tissue. Any disruption or loss of key suppliers could cause product shortages and lost revenue.

    From the company's own filingsWould hit how fast sales growGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025

  4. Competition from Large Medical Device Companies

    Major competitors have substantially larger financial, marketing, and distribution resources, and can leverage existing hospital relationships or aggressive pricing to capture market share.

    From the company's own filingsWould hit how fast sales growGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025

  5. Open FDA Warning Letter for ExcelsiusGPS

    An FDA warning letter regarding complaint handling and medical device reporting for ExcelsiusGPS remains open. Failure to satisfy FDA requirements could trigger fines, recalls, or sanctions.

    From the company's own filingsWould hit how much of each sale it keepsGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025

  6. Integration Complexity of Large Acquisitions

    Integrating major acquisitions like NuVasive and Nevro involves operational risks. Failure to achieve anticipated cost synergies or sales force retention could hurt profitability.

    From the company's own filingsWould hit how much of each sale it keepsGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025

  7. The revised guidance implies Q4 2026 revenue below Q4 2025, and Nevro is still declining.

    From our researchWould hit how fast sales growYahoo Finance Q3 2026 call highlights

  8. Management cut its revenue outlook while holding EPS guidance, which suggests cost cutting is carrying earnings and may not repeat.

    From our researchWould hit how much of each sale it keepsGMED Q3 2026 8-K

Is it a good business?

From 2023 to 2025 it earned between 3% and 10% on the capital invested in it, a median of 4%. Its cost of capital in the latest valuation is 9.5%; returns were above it in 1 of the 3 years.

From 2016 to 2025 it earned between 2% and 13% on its shareholders' equity, a median of 11%.

Over 10 years its operating margin ranged from 7¢ to 27¢ per sales dollar, a median of 20¢. Gross margin ran from 59¢ to 78¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital10%
20162025

Cost of capital 9.5%

Return on equity12%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 19%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares has held roughly steady over the past year.

It holds $516.8M more in cash than it owes.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $70.50. Our put its value between $34.52 and $72.43, with $53.41 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $34.52

Sales were flat to slightly down this past year as the Nevro pain-device business shrank, and this scenario assumes that weakness continues, the core spine business grows slowly, and profits stay around today's level.

Base case, $53.41

After years of fast, deal-driven growth, sales have levelled off, and this scenario assumes they return to steady mid-single-digit growth once the shrinking Nevro business stabilizes, with profits holding near their recent improved level.

Bull case, $72.43

This scenario assumes the recent sales stall is temporary: delayed new products launch, the surgical-robot business keeps growing quickly, and the company returns to the solid growth and rising profits it showed before its big acquisitions.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 32%

For Globus Medical to be worth today's $70.50, sales would need to grow about 11.0% a year. We assume 4.0%. Over the last 5 years, sales grew 27.2% a year.

−10%0%+10%+20%+30%+40%We assume 4.0%Price needs 11.0%Past 5 yrs 27.2%

Or, if sales grow 4.0% as we assume, the price works with a profit margin of 31.6% (we assume 23.5%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 11.0% a year?

Try your own numbers

We're moderately sure of this range: it scores 63 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $53.41 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average4.0%
  • Operating margin23.5%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$53.41 -24.2%

Build